Balance of infection-enhancing and neutralizing antibodies induced by a dengue tetravalent DNA vaccine in a mouse model

被引:6
作者
Konishi, Eiji [1 ,2 ,3 ,4 ,5 ]
Miyagawa, Yuko [1 ]
机构
[1] Kobe Univ, Grad Sch Hlth Sci, Dept Int Hlth, Suma Ku, Kobe, Hyogo 6540412, Japan
[2] Kobe Univ, Grad Sch Med, Dept Microbiol & Infect Dis, Chuo Ku, Kobe, Hyogo 6500017, Japan
[3] Mahidol Univ, Fac Trop Med, BIKEN Endowed Dept Dengue Vaccine Dev, Bangkok 10400, Thailand
[4] Osaka Univ, Res Fdn Microbial Dis, Osaka, Japan
[5] Osaka Univ, Microbial Dis Res Inst, Osaka, Japan
基金
日本科学技术振兴机构;
关键词
Dengue; Antibody-dependent enhancement; Antibodies; Neutralizing; Dengue Vaccines; DEPENDENT ENHANCEMENT; ANTIGENIC DETERMINANTS; CLINICAL-TRIAL; 4; SEROTYPES; VIRUS; TYPE-2; IMMUNOGENICITY; FORMULATIONS; SAFETY;
D O I
10.1016/j.micinf.2011.06.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Most dengue vaccines currently under development are designed to induce neutralizing antibodies. Although neutralizing antibodies are believed to be protective, most of the antibody species that have neutralizing activities also have infection-enhancing activities at subneutralizing doses. Thus, the balance of neutralizing and enhancing activities induced by a dengue tetravalent vaccine was analyzed in this study in a DNA vaccine model using mice. The balance was measured using semi-adherent K562 cells in an assay system we previously developed. This system detected enhancing activities in sera from mice immunized with the vaccine when complement was absent from the virus antibody mixture in this assay. Mice passively transferred with vaccinated mouse sera or monoclonal antibodies that possessed neutralizing activities as determined on Vero cells, also showed enhancing activities in their sera during the course of antibody waning in the absence of complement. However, these enhancing activities were abolished or altered to neutralizing activities in the presence of complement in our assay system, except in mice passively transferred with a monoclonal antibody of isotype IgG1. Thus, enhancing activities were not shown in mice immunized with a DNA vaccine as far as complement was included in our in vitro assay system. (C) 2011 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1091 / 1098
页数:8
相关论文
共 36 条
[1]  
[Anonymous], HEIGHTS
[2]   Complement and its role in protection and pathogenesis of flavivirus infections [J].
Avirutnan, Panisadee ;
Mehlhop, Erin ;
Diamond, Michael S. .
VACCINE, 2008, 26 :I100-I107
[3]   Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys [J].
Blaney, JE ;
Matro, JM ;
Murphy, BR ;
Whitehead, SS .
JOURNAL OF VIROLOGY, 2005, 79 (09) :5516-5528
[4]   Antibody-mediated neutralization of flaviviruses: A reductionist view [J].
Dowd, Kimberly A. ;
Pierson, Theodore C. .
VIROLOGY, 2011, 411 (02) :306-315
[5]  
Frank M.M., 1989, Fundamental Immunology, P679
[6]   IDENTIFICATION OF DISTINCT ANTIGENIC DETERMINANTS ON DENGUE-2 VIRUS USING MONOCLONAL-ANTIBODIES [J].
GENTRY, MK ;
HENCHAL, EA ;
MCCOWN, JM ;
BRANDT, WE ;
DALRYMPLE, JM .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1982, 31 (03) :548-555
[7]   Immunopathological mechanisms in dengue and dengue hemorrhagic fever [J].
Green, Sharone ;
Rothman, Alan .
CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (05) :429-436
[8]  
Gubler D.J., 2007, FIELDS VIROLOGY, V5th, P1153
[9]   Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine:: Phase I clinical trial for safety and immunogenicity [J].
Guirakhoo, Farshad ;
Kitchener, Scott ;
Morrison, Dennis ;
Forrat, Remi ;
McCarthy, Karen ;
Nichols, Richard ;
Yoksan, Sutee ;
Duan, Xiaochu ;
Ermak, Thomas H. ;
Kanesa-Thasan, Niranjian ;
Bedford, Philip ;
Lang, Jean ;
Quentin-Millet, Marie-Jose ;
Monath, Thomas P. .
HUMAN VACCINES, 2006, 2 (02) :60-67
[10]   Neutralization and antibody-dependent enhancement of dengue viruses [J].
Halstead, SB .
FLAVIVIRUSES: PATHOGENESIS AND IMMUNITY, 2003, 60 :421-467